Volume 21, Issue 2 (5-2018)
J Arak Uni Med Sci 2018, 21(2): 55-64 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alimoradian A, Shamsi M, Faraji F, Ahmadi M, Sayyedi S E. Evaluation of the Serum Melatonin Levels in the Treatment of Patients with Multiple Sclerosis. J Arak Uni Med Sci 2018; 21 (2) :55-64
URL: http://jams.arakmu.ac.ir/article-1-5484-en.html
URL: http://jams.arakmu.ac.ir/article-1-5484-en.html
1- Department of Pharmacology, School of Medicine, Arak University of Medical Sciences, Arak, Iran , alimoradian@arakmu.ac.ir
2- Department of Public Health, School of Health, Arak University of Medical Sciences, Arak, Iran.
3- Department of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
4- Al-Zahra Clinic Laboratory, Arak University of Medical Sciences, Arak, Iran
5- Imam Sadegh Hospital laboratory of Delijan, Arak University of Medical Sciences, Arak, Iran
2- Department of Public Health, School of Health, Arak University of Medical Sciences, Arak, Iran.
3- Department of Neurology, School of Medicine, Arak University of Medical Sciences, Arak, Iran
4- Al-Zahra Clinic Laboratory, Arak University of Medical Sciences, Arak, Iran
5- Imam Sadegh Hospital laboratory of Delijan, Arak University of Medical Sciences, Arak, Iran
Abstract: (3721 Views)
Abstract
Background: Multiple sclerosis (MS) is a myelinating inflammation and an impairment of neuronal cell regeneration in the central nervous system with unknown causes. The aim of this study was to evaluate serum melatonin levels in the treatment of patients with multiple sclerosis.
Materials and Methods: A prospective study and a Cohort were conducted on 40 MS patients with multiple sclerosis patients referring to instituate MS in Arak city for one year. In this study, patients who were treated with interferon-moderating drugs and who had not been treated for more than one year were randomly selected. A questionnaire containing demographic information and clinical information and separation of interacting factors was completed and completed. Clinical information included MRI, VEP, EDSS (Expanded Disability Status Scale) score, and clinical symptoms. The patients also received peripheral blood samplers 3 times in 6 months intervals to measure melatonin and their melatonin levels, and then the relationship between the data obtained from the patient's clinical data, EDSS, serum melatonin levels using the software SPSS with ANOVA and Post-hoc statistical analyzed.
Results: In patients with MS, in spite of receiving drug treatment, the level of melatonin as an antioxidant decreased in second order sampling, which is consistent with the deterioration of the patient's clinical condition (EDSS test), and this is not observed in the control group.
Conclusion: According to the findings of this study, it can be argued that the level of melatonin is a measurable objective and measurable variable (with the help of ELISA) that can be used in the follow-up of these patients, along with clinical evaluations and questionnaires.
Background: Multiple sclerosis (MS) is a myelinating inflammation and an impairment of neuronal cell regeneration in the central nervous system with unknown causes. The aim of this study was to evaluate serum melatonin levels in the treatment of patients with multiple sclerosis.
Materials and Methods: A prospective study and a Cohort were conducted on 40 MS patients with multiple sclerosis patients referring to instituate MS in Arak city for one year. In this study, patients who were treated with interferon-moderating drugs and who had not been treated for more than one year were randomly selected. A questionnaire containing demographic information and clinical information and separation of interacting factors was completed and completed. Clinical information included MRI, VEP, EDSS (Expanded Disability Status Scale) score, and clinical symptoms. The patients also received peripheral blood samplers 3 times in 6 months intervals to measure melatonin and their melatonin levels, and then the relationship between the data obtained from the patient's clinical data, EDSS, serum melatonin levels using the software SPSS with ANOVA and Post-hoc statistical analyzed.
Results: In patients with MS, in spite of receiving drug treatment, the level of melatonin as an antioxidant decreased in second order sampling, which is consistent with the deterioration of the patient's clinical condition (EDSS test), and this is not observed in the control group.
Conclusion: According to the findings of this study, it can be argued that the level of melatonin is a measurable objective and measurable variable (with the help of ELISA) that can be used in the follow-up of these patients, along with clinical evaluations and questionnaires.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
